Everett, Washington – A pivotal moment has transpired in the biopharmaceutical landscape following the acquisition of a significant 270,000-square-foot facility by Breakthrough Properties, a life sciences real estate company. Following a protracted period of inactivity, the Everett facility, formerly constructed by Seattle biotech giant Seagen, is now leased for a remarkable 21-year term to an unnamed global biopharmaceutical company. This move represents a strategic realignment for Pfizer, a company that previously held a substantial stake in Seagen before its acquisition by Pfizer in 2023. Seagen invested approximately $350 million in the facility’s initial construction, designed to serve as a hub for drug manufacturing, quality control, warehousing, and distribution. The facility’s location, situated approximately 25 miles north of Seattle along the I-5 corridor, marks Breakthrough Properties’ first significant investment within the Puget Sound region, a burgeoning area of pharmaceutical manufacturing. According to a statement released by Breakthrough Properties, the company’s acquisition was driven by Pfizer’s ongoing evaluation of its manufacturing network and a strategic decision to wind down the facility’s construction. The facility’s history is intertwined with Seagen’s tenure at Everett, having been a key component of the company’s broader expansion plan. The deal, finalized through a joint venture between Tishman Speyer and Bellco Capital, has been hailed as a reflection of increased investment in U.S. manufacturing capacity by major drugmakers, with reports indicating over $600 billion in recent commitments to expand domestic production and strengthen supply chains nationally. The Everett facility’s integration into Breakthrough Properties’ portfolio underscores the company’s focus on strategically positioned life sciences properties across the United States and Europe. While Breakthrough Properties has remained tight-lipped regarding the specific tenant and anticipated move-in date, the acquisition signifies a crucial shift in Pfizer’s long-term strategy, potentially impacting the regional biopharmaceutical ecosystem. The facility’s history, intertwined with Seagen’s previous presence, provides a compelling narrative of a legacy facility transitioning into a new chapter, aligning with Pfizer’s broader goals for expanded domestic production and supply chain resilience. The facility’s location also contributes to the area’s growing role as a vital hub for pharmaceutical manufacturing within the Puget Sound region, bolstering the local economy and supporting the advancement of the biopharmaceutical industry. The precise nature of the new tenant and the implications for the existing workforce remain to be fully elucidated, but the acquisition undoubtedly strengthens the competitive landscape within the region.”
Watch Related Video
Source: Tech
